$2.76
-0.12 (-4.17%)
Open$2.89
Previous Close$2.88
Day High$2.89
Day Low$2.71
52W High$4.53
52W Low$1.33
Volume—
Avg Volume402.7K
Market Cap85.66M
P/E Ratio21.49
EPS$0.04
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+368.5% upside
Current
$2.76
$2.76
Target
$12.93
$12.93
$7.67
$12.93 avg
$16.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 79.77M | 84.60M | 15.02M |
| Net Income | -63,618,983 | -60,724,450 | -500,427 |
| Profit Margin | -79.8% | -75.8% | -3.3% |
| EBITDA | -146,104,325 | -147,204,484 | -867,054 |
| Free Cash Flow | — | — | -309,659 |
| Rev Growth | -5.7% | -5.7% | +23.3% |
| Debt/Equity | 2.58 | 2.58 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |